ACDM News Item

U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties

Date: January 23, 2025

The U.S. Food and Drug Administration has issued its first guidance on the use of Artificial Intelligence (AI) for the development of drug and biological products.

This draft guidance, titled ‘Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products,’ has been put together to provide recommendations on the use of AI intended to support a regulatory decision about a drug or biological product’s safety, effectiveness, or quality.

Read here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

Explore More News

Regulatory Considerations DMEG Update – September 2024

The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .

Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)

This article has been submitted by Leeni Joshua of ICON plc Introduction: Digital Data . . .

Guidance for Industry: Conducting Clinical Trials With Decentralized Elements

The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .

Welcome FGK Clinical Research as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .

Welcome LINK Medical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome LINK Medical as . . .

Welcome Zilla Clinicals as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Zilla Clinicals . . .

Challenge ChatGPT: CDMs vs AI

Following a recent Hot Topic discussion that explained how machine learning models are . . .

Welcome Boehringer Ingelheim as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Boehringer . . .

Welcome Datacapt as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Datacapt as a . . .

Welcome Climedo as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Climedo as a . . .

Clinical Trials for Medicines – New Notification Scheme

The MHRA have recently launched a new notification scheme, the first step in their . . .

EMA Management Board: Highlights of October 2023 meeting

The EMA’s Management Board met on 5 October in Amsterdam. The article below covers the . . .